<DOC>
	<DOCNO>NCT01366131</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double-blind , placebo-controlled trial design evaluate efficacy safety MEGF0444A combine paclitaxel + carboplatin + bevacizumab therapy patient histologically cytologically document inoperable , locally advanced , metastatic ( Stage IV ) , recurrent non-squamous NSCLC .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy MEGF0444A Combination With Carboplatin , Paclitaxel Bevacizumab Patients With Advanced Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy Advanced Disease ( NILE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically document inoperable ( Stage IV ) recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) . Diagnoses nonsquamous NSCLC base sputum cytology alone acceptable . Mixed tumor categorize accord predominant cell type . ECOG performance status 0 1 Life expectancy &gt; 12 week Measurable disease , define RECIST 1.1 Adequate hematologic end organ function Prior therapy ( include chemotherapy , antibody therapy , tyrosine kinase inhibitor , radiotherapy , immunotherapy , hormonal therapy investigational therapy ) Day 1 Cycle 1 treatment Stage IV recurrent NSCLC . Patients receive prior adjuvant chemotherapy radiotherapy NSCLC exclude time interval completion adjuvant therapy disease progression &gt; 12 month . Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment Malignancies NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent Pregnant lactate woman Active infection require IV antibiotic BevacizumabSpecific Exclusions : Histologically cytologically document inoperable , locally advanced , mixed nonsmall cell small cell tumor mix adenosquamous carcinoma predominant squamous component Evidence tumor invade major blood vessel image Evidence central nervous system ( CNS ) metastases History stroke transient ischemic attack ( TIAs ) within 6 month prior Day 1 Significant vascular disease within 6 month prior Day 1 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>